Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial
Abstract
Increasing levels of tumor markers such as carcinoembryonic antigen, mucin-like carcinoma-associated antigen (MCA), CA 15.3, and monoclonal antibody H23 in breast cancer patients following the treatment of the primary disease and adjuvant radiation and chemotherapy reflect subclinical development of metastatic disease. Overt metastatic disease is usually incurable and prolongation of life at this stage is impossible, and the treatment is only palliative. The efficacy of tamoxifen, a least-toxic agent, in the treatment of early and minimal metastatic disease detected only by increasing serum levels of MCA was studied prospectively in a randomized study. Our preliminary, albeit encouraging, results showed that the rate of relapse within a median follow-up period of 11 months was 24.1% in the control arm as compared with 0% in the tamoxifen arm (Fisher's exact test,P=0.012). None of the patients with a relapse had positive progesterone receptors (PR). We may carefully conclude that early treatment may be warranted in young patients with negative PR and continuously increasing serum levels of the marker.
Key words
Breast cancer Tamoxifen Metastatic disease Tumor markers Carcinoembryonic antigen Mucin-like carcinoma-associated antigen CA 15.3Preview
Unable to display preview. Download preview PDF.
References
- 1.Barak M, Steiner M, Finkel B, Abrahamson J, Antal S, Gruener N (1990) CA-15.3, TPA and MCA as markers for breast cancer. Eur J Cancer 26: 577Google Scholar
- 2.Bombardieri E, Pizzichetta M, Veronesi P, Eregni E, Bogni A, Maffioli L, Saccanti-Jotti G, Bassetto MA, Zurrida S, Costa A (1993) CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 29A: 144Google Scholar
- 3.Cavalli F, Beer M, Martz G (1983) Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer Report of the Swiss group for clinical cancer research. BMJ 286: 5Google Scholar
- 4.Cooper EH, Forbes MA, Hancock AK, Price JJ, Parker D (1989) An evaluation of mucin-like carcinoma associated antigen (MCA) in breast cancer. Br J Cancer 59: 797Google Scholar
- 5.Hammer J, Track C, Hohenwallner W, Seewald DH, Zoidl JP, Wimmer E (1992) MCA and CA-15.3 in the follow-up of patients with breast cancer. Strahlenther Onkol 168: 102Google Scholar
- 6.Henderson IC, Harris JR, Kinne DW, Hellman S (1989) Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer — principles and practice of oncology. J. B. Lippincott, Philadelphia, pp 1197–1268Google Scholar
- 7.Jager W, Merkle E, Lang N (1991) Erlanger tumor marker study on breast cancer. J Tumor Marker Oncol 6: 56Google Scholar
- 8.Merimsky O, Inbar M, Hareuveni M, Witenberg B, Wolman Y, Chaitchik S (1991) Serial serum MCA measurements in the follow-up of breast cancer patients. Eur J Cancer 27: 1440Google Scholar
- 9.Merimsky O, Hareuveni M, Inbar M, Horev J, Keydar I, Kovner F, Chaitchik S (1993) Increasing serum levels of mucin-like carcinoma associated antigen and mucinous antigen H23 in clinically disease free breast cancer patients. Diagn Oncol 3: 61Google Scholar
- 10.Mueller-Brand J, Macke H, Hegialjai T (1988) Clinical value of a mucin-like carcinoma-associated antigen (MCA) in the monitoring of breast cancer patients. J Nucl Med 29: 894Google Scholar
- 11.Rasoul-Rockenschaub S, Zielinski CC, Kubista E (1989) Diagnostic value of MCA in breast cancer. Eur J Cancer Clin Oncol 25: 1067Google Scholar
- 12.Steger GG, Mader R, Derfler K, Moser K, Dittrich C (1989) Mucin-like cancer-associated antigen (MCA) compared with CA-15.3 in advanced breast cancer. Klin Wochenschr 67: 813Google Scholar
- 13.Tomiak E, Piccart M (1993) Routine follow-up of patients after primary therapy for early breast cancer: changing concepts and challenges for the future. Ann Oncol 4: 199Google Scholar
- 14.Tomin R, Donegan WL (1987) Screening for recurrent breast cancer — its effectiveness and prognostic value. J Clin Oncol 5: 62Google Scholar
- 15.Tsarfaty I, Chaitchik S, Hareuveni M, Horev J, Hizi A, Wreschner DH, Keydar I (1989) H23 monoclonal antibody recongizes a breast tumor associated antigen: clinical and molecular studies. In: Ceriani RL (ed) Breast cancer immunodiagnosis and immunotherapy. Plenum, New York, pp 161–169Google Scholar